Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects
Study identifier:D0190C00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Randomized, Double-blind (with-in panel), Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Healthy Elderly Volunteers After Oral Multiple Ascending Doses of AZD0328
Medical condition
Alzheimer’s disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD0328, Placebo
Sex
All
Actual Enrollment
112
Study type
Interventional
Age
60 Years - 80 Years
Date
Study Start Date: 01 Nov 2007
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD0328 Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel. |
| Placebo Comparator: 2 | Drug: Placebo Administered orally as a solution once per day on day 1, and then day 3 through to day 14. |
Contacts
Investigators
Principal Investigator
Wolfgang Kühn
Quintiles ABStrandbodgatan 1S-753 23 Uppsala
